Naringin alters the cholesterol biosynthesis and antioxidant enzyme activities in LDL receptor-knockout mice under cholesterol fed condition.
The purpose of the current study was to evaluate the lipid lowering and antioxidant capacity of naringin in LDL receptor knockout (LDLR-KO) mice fed a cholesterol (0.1 g/100 g) diet. As such, naringin or lovastatin (0.02 g/100 g) was supplemented in a cholesterol diet for 6 weeks. The naringin and lovastatin supplementation significantly lowered the plasma total cholesterol level compared to the control group. The plasma and hepatic triglyceride level was only lowered by the lovastatin supplement, while the hepatic cholesterol content was lowered by both the naringin and lovastatin supplements compared to the control group. The hepatic HMG-CoA reductase activity was significantly lower in the naringin and lovastatin supplemented groups than in the control group, whereas the ACAT activity was unaffected. The excretion of total sterol was significantly higher in the naringin and lovastatin groups compared to the control group due to significant changes in the acidic and neutral sterol, respectively. When comparing the hepatic antioxidant enzyme activities, the superoxide dismutase, catalase, and glutathione reductase activities were all significantly higher in the naringin-supplemented group than in the control group, while only the lovastatin supplement increased the glutathione reductase activity. Accordingly, the current results confirmed that naringin lowers the plasma cholesterol level via the inhibition of hepatic HMG-CoA reductase activity and increases the excretion of fecal sterol. Naringin was also found to improve the activities of hepatic antioxidant enzymes against oxidative stress in a hypercholesterolemic animal model, i.e. cholesterol-fed LDLR-KO mice.
Kim
Hye-Jin
HJ
Department of Food Science and Nutrition Kyungpook National University, 1370 Sank-Yuk Dong Puk-Ku, Daegu, 702-701, South Korea.
Oh
Goo Taeg
GT
Park
Yong Bok
YB
Lee
Mi-Kyung
MK
Seo
Hyun-Ju
HJ
Choi
Myung-Sook
MS
D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology; D002784:Cholesterol / Q000096:biosynthesis*; D002791:Cholesterol, Dietary / Q000008:administration & dosage*; D004032:Diet; D005243:Feces / Q000737:chemistry; D044950:Flavanones / Q000494:pharmacology*; D006903:Hydroxymethylglutaryl CoA Reductases / Q000378:metabolism; D050356:Lipid Metabolism; D008099:Liver / Q000737:chemistry / Q000201:enzymology / Q000378:metabolism; D008148:Lovastatin / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D011897:Random Allocation; D011973:Receptors, LDL / Q000235:genetics / Q000378:metabolism*; D002785:Sterol O-Acyltransferase / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism
D000924:Anticholesteremic Agents; D002791:Cholesterol, Dietary; D044950:Flavanones; D011973:Receptors, LDL; D002784:Cholesterol; D008148:Lovastatin; D006903:Hydroxymethylglutaryl CoA Reductases; D013482:Superoxide Dismutase; D002785:Sterol O-Acyltransferase; C005274:naringin